Nutex Health, a Houston-based microhospital operator, is utilizing specific regulatory exemptions and federal arbitration mechanisms to maximize revenue.

Nutex Health 是一家總部位於休斯頓的微型醫院營運商，該公司利用特定的監管豁免和聯邦仲裁機制來最大化收益。

The operational strategy of Nutex Health is predicated upon the avoidance of Medicare contracts. This strategic omission exempts the majority of its facilities from federal mandates requiring the treatment of patients regardless of their financial solvency. Consequently, the organization has been reported to demand upfront payment from uninsured individuals, a practice that has resulted in the denial of care to patients presenting with acute cardiac symptoms. While the entity asserts that a voluntary screening process is implemented to identify life-threatening conditions, patient testimonies suggest a failure in the execution of these protocols.

Nutex Health 的營運策略是基於避開 Medicare 合約。這種策略性省略使其大部分設施免於遵守聯邦指令，即無論患者的財務能力如何都必須提供治療。因此，據報導該機構要求未投保人士預先付款，這種做法導致出現急性心臟症狀的患者被拒絕治療。雖然該實體聲稱已實施自願篩查程序以識別危及生命的狀況，但患者的證詞顯示這些方案在執行上存在失敗。

Financial stabilization of the firm was achieved through the utilization of the Independent Dispute Resolution process established by the No Surprises Act. Following a period of near-insolvency precipitated by the prohibition of balance billing, the company's revenue tripled and profits increased nearly twelvefold via the submission of arbitration disputes. Furthermore, the organization's fiscal practices include high-cost billing for diagnostic services, with reports of insurance charges ranging from $2,000 to $21,000 for COVID-19 testing.

該公司的財務穩定是透過利用《無驚法案》（No Surprises Act）建立的獨立爭議解決程序而實現的。在因禁止餘額開單而導致接近破產後，該公司透過提交仲裁爭議，使收入增加三倍，利潤增加近十二倍。此外，該機構的財務做法包括對診斷服務收取高價，據報導 COVID-19 檢測的保險費用在 2,000 至 21,000 美元之間。

Institutional risks are compounded by a partnership with HaloMD, a Texas-based intermediary currently embroiled in litigation regarding unethical profit-sharing arrangements with surgeons. Investors have initiated legal action alleging that Nutex Health concealed this relationship, thereby exposing the company to significant liability. These concerns are mirrored by active regulatory investigations currently being conducted in the states of Idaho and New Mexico.

由於與 HaloMD 的合作，機構風險進一步增加。HaloMD 是一家總部位於德州的中間商，目前正因與外科醫生之間不道德的利潤分享安排而陷入訴訟。投資者已提起法律訴訟，指控 Nutex Health 隱瞞了這段關係，從而使公司面臨重大責任。這些憂慮也反映在愛達荷州和新墨西哥州目前正在進行的監管調查中。

Nutex Health remains under regulatory scrutiny while continuing to leverage federal arbitration to sustain high profit margins.

Nutex Health 在繼續利用聯邦仲裁以維持高利潤率的同時，仍處於監管審查之中。